Profound Medical Corp. (PROF) News
Filter PROF News Items
PROF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PROF News Highlights
- PROF's 30 day story count now stands at 5.
- Over the past 23 days, the trend for PROF's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CPT and TALK are the most mentioned tickers in articles about PROF.
Latest PROF News From Around the Web
Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate DiseasesTORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, with sponsorship and support from multiple physician specialty societies, the American Medical Association (“AMA”) has established three new Current Procedural Terminology (“CPT®’) Category 1 codes for MRI-Monitored |
Profound Medical Announces Upcoming Investor EventsTORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following investor events in June: PRO-Talk Episode 5, “Unlocking the Potential of TULSA-PRO®”: Profound will be hosting a live webinar on Tuesday, June 6, 2023 at 6:00 p.m. ET, during which the following esteemed TUSLA-PRO® |
Profound Medical to Participate in A.G.P.’s Virtual Healthcare ConferenceTORONTO, May 18, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in A.G.P.’s Virtual Healthcare Conference on Wednesday, May 24, 2023. The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available. About P |
Profound Medical Annual and Special Meeting of Shareholders Voting ResultsTORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 13,437,920 common shares, representing 63.64% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company’s management informa |
Profound Medical Announces First Quarter 2023 Financial ResultsTORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reportin |
TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting– Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whole gland or focal treatment for prostate disease – – FARP study provides Level 1 evidence that focal therapy with TULSA has a lower complication rate compared to RALP – TORONTO, May 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets custo |
Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to FollowTORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in t |
Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor ConferenceTORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. Th |
Profound Medical Announces Fourth Quarter and Full Year 2022 Financial ResultsCompany confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSATORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2022. Unless specified otherwise, all amounts in this pres |
Profound Medical to Present at the 43rd Annual Cowen Health Care ConferenceTORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time. The presentation will be br |